NexgenRX Inc. (NXG) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of NexgenRX Inc. C$0.66, price C$0.60, upside +10.0%, quality 69 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch NexgenRX Inc. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range C$0.1818 – C$0.7000 · fair‑value band C$0.4950 – C$0.9570 · the C$0.6000 price screens below the C$0.6600 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 3 fiscal years are left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Sep 23, 2026.
Follow NexgenRX in your weekly email
Every Wednesday you see whether NexgenRX is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
NexgenRx Inc. administers, adjudicates, and pays drug, dental, and other extended health-care claims for the beneficiaries of health benefit plans underwritten by its customers in Canada. The company offers NexSys claims management; NexAdmin plan administration; and NexPSPAssist patient support programs.
Show more
NexgenRx Inc. administers, adjudicates, and pays drug, dental, and other extended health-care claims for the beneficiaries of health benefit plans underwritten by its customers in Canada. The company offers NexSys claims management; NexAdmin plan administration; and NexPSPAssist patient support programs. It also provides proprietary computer software, and ancillary services. NexgenRx Inc. was incorporated in 2003 and is headquartered in Toronto, Canada.
Stock analysis
NexgenRX Inc. (NXG) currently trades at C$0.6000, while our model-based Fair Value estimate is C$0.6600, implying the stock looks roughly 9.1% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of C$0.7500 per share, and 10 of the 24 models we run sit above the C$0.6000 price.
Bear case: the Asset-Based group reads lowest at C$0.0700, and 14 of the 24 models stay below the price. Evidence for this calculation is low.
Scenario range: C$0.4950 (bear) to C$0.9570 (bull), the price of C$0.6000 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 69/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
NexgenRX Inc. reported revenue of C$17.9M in FY2025 versus C$11.8M in FY2021, a compound +10.9%/yr. Reported net income was C$1.3M in FY2025, compounding −24.7%/yr from FY2021.
Key figures
Market cap C$42.7M (≈ $30.2M) · P/E ratio 30.0 · P/S ratio 2.16 · EPS (TTM) C$0.0200 · Dividend yield 2.5% · Net margin 7.2% · Return on equity 23.5% · Return on assets (EBIT) 3.6%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The share trades about 14% below its 52-week high and 96% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 10%, NXG screens cheaper than that median.
Fair Value models
Bear C$0.4950Fair Value C$0.6600Bull C$0.9570
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (C$0.0037 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.91/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+8.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.2%
Start year 2020 (pandemic). Over 10 years: +14.4% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.4%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−13.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year−16.1%
Dividend (yield on the price)2.5%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.20% → 13%
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−9.1%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Canada: IMF forecast 2.1% a year to 2030, 2.6% from 2016 to 2025) that is about −11.0% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 133 stocks
Beats the industry median on 12/15 measures
Overall it ranks above its industry peers.
Valuation
Quality Score69 · Top 25%
Fair Value upside+10% · Above median
Profitability
Return on equity (TTM)24% · Top 25%
Return on assets5% · Top 25%
Net margin (TTM)11% · Top 25%
Operating margin (TTM)25% · Top 25%
Growth and dividend
Revenue growth12% · Above median
Dividend yield (TTM)2.5% · Above median
Balance sheet
Debt / equity0.04× · Above median
Valuation Multiplesvs Health Information Services median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "NexgenRX Inc. Fair Value". https://www.fairvalue-calculator.com/stock/NXG
Frequently asked questions
Is NexgenRX Inc. (NXG) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of C$0.6600 versus a price of C$0.6000, about +10% upside (undervalued).
What is the fair value of NXG?
Our model-based fair value for NexgenRX Inc. is C$0.6600 (as of Sep 23, 2026), built from audited fundamentals. The current price: C$0.6000.
What is the quality score of NXG?
NexgenRX Inc. has a Quality Score of 69/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for NexgenRX Inc. (NXG)?
Our model-based price target is the fair value of C$0.6600 (as of Sep 23, 2026) from 24 valuation models. Cautious scenario C$0.4950, optimistic scenario C$0.9570. It is a calculation from audited fundamentals, not an analyst target.
What is the NexgenRX Inc. stock forecast for 2026?
Our models put fair value at C$0.6600, about +10% upside versus a price of C$0.6000 (undervalued). Cautious scenario C$0.4950, optimistic scenario C$0.9570. The calculation is refreshed regularly with new filings.
What is the revenue of NexgenRX Inc. (NXG)?
NexgenRX Inc. reported trailing-twelve-month revenue of about C$18.5M (latest available figure, as of Sep 23, 2026).
Does NexgenRX Inc. pay a dividend?
NexgenRX Inc. currently shows a dividend yield of about 2.50% relative to its recent price (as of Sep 23, 2026).
What growth is priced into NexgenRX Inc. (NXG)?
For today's price to be fair in a discounted-cash-flow model, NexgenRX Inc. would have to grow free cash flow by -9.1 % per year for five years (discount rate 8.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +10.2 % per year. As of Sep 23, 2026.
What discount rate (WACC) does the fair value of NXG use?
Our models discount NexgenRX Inc. at 8.4 %: a base by market capitalisation (nano), damped by beta 0.53, country premium for Canada. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For NexgenRX Inc. that is -9.1 % per year a year over ten years, using the same discount rate (8.4 %) and the same formula as our fair value.
How much growth has NexgenRX Inc. (NXG) delivered so far?
Over the past 5 years revenue at NexgenRX Inc. grew +10.2 % a year. The price currently implies -9.1 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of NexgenRX Inc. (NXG) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into NexgenRX Inc. (-9.1 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of NexgenRX Inc. (NXG)?
The free-cash-flow yield on the price is 10.85 %: that much free cash flow NexgenRX Inc. produces per unit of market value. When it exceeds the discount rate of our models (8.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of NexgenRX Inc. (NXG)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For NexgenRX Inc. it is C$0.6600 per share (as of Sep 23, 2026), against a price of C$0.6000. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is NexgenRX Inc. stock overvalued or undervalued in 2026?
As of Sep 23, 2026, NXG trades below its calculated fair value: price C$0.6000, fair value C$0.6600, a gap of about +10% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of NXG?
No. The price is what the market pays today (C$0.6000); the fair value is what the company's own numbers justify (C$0.6600). For NexgenRX Inc. the two are C$0.0600 per share apart. That gap is exactly why we show both numbers side by side.
How much is NexgenRX Inc. worth?
The market values NexgenRX Inc. at about C$42.7M (market capitalisation, as of Sep 23, 2026). Per share that is C$0.6000; our models calculate a fair value of C$0.6600 per share.
What do the bullish and bearish scenarios say about NXG?
Our models span a range for NexgenRX Inc.: cautious scenario C$0.4950, base C$0.6600, optimistic C$0.9570 per share (as of Sep 23, 2026, price C$0.6000). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of NXG?
NexgenRX Inc. trades at a price-to-earnings ratio of 30.0 (as of Sep 23, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of C$0.6600 is built from several models across several years. Other multiples: PEG 6.5, P/B 4.0, P/S 1.6, EV/EBITDA 8.9.
What is the PEG ratio of NXG?
The PEG ratio of NexgenRX Inc. is 6.53 (P/E divided by earnings growth, as of Sep 23, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of NexgenRX Inc. (NXG)?
Balance-sheet figures for NexgenRX Inc. (as of Sep 23, 2026): return on equity 23.5%, debt of 0.04 per unit of equity. They feed the Quality Score of 69/100, which measures business quality independently of the share price.
How far is NXG from its 52-week high?
NexgenRX Inc. trades at C$0.6000, about 14% below its 52-week high of C$0.7000 and 96% above the low of C$0.3060 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of C$0.6600 is for.
Which stocks are comparable to NexgenRX Inc.?
From the same area (Healthcare) we also value Veeva Systems Inc, Pro Medicus Limited, BrightSpring Health Services, Inc, HealthEquity, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is NexgenRX Inc. stock attractive at the current price?
The data as of Sep 23, 2026: price C$0.6000, calculated fair value C$0.6600 (+10%), Quality Score 69/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of NXG calculated?
We run NexgenRX Inc. through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of C$0.6600, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. NexgenRX Inc. currently trades 10 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of NexgenRX Inc. (NXG)?
The closing price on Sep 23, 2026 was C$0.6000. Our model-based fair value is C$0.6600, about +10% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with NexgenRX Inc. right now?
A fairly wide model range (C$0.4950 to C$0.9570) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of NexgenRX Inc.
How large is the market capitalisation of NexgenRX Inc. (NXG)?
The market capitalisation of NexgenRX Inc. is C$42.7M (≈ $30.2M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of NexgenRX Inc. (NXG)?
The price-to-sales ratio of NexgenRX Inc. is 2.16 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of NexgenRX Inc. (NXG)?
Earnings per share at NexgenRX Inc. are C$0.0200 (price ÷ EPS = P/E 30.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of NexgenRX Inc. (NXG)?
The dividend yield of NexgenRX Inc. is 2.5% (payout 75.0%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of NexgenRX Inc. (NXG)?
The net margin of NexgenRX Inc. is 7.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of NexgenRX Inc. (NXG)?
The return on equity (ROE) of NexgenRX Inc. is 23.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of NexgenRX Inc. (NXG)?
On an EBIT basis the return on assets of NexgenRX Inc. is 3.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of NexgenRX Inc. (NXG)?
The operating margin of NexgenRX Inc. is 25.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at NexgenRX Inc. (NXG)?
Revenue at NexgenRX Inc. is growing +11.6% versus a year earlier (3y avg +11.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at NexgenRX Inc. (NXG)?
Earnings per share at NexgenRX Inc. are growing +167% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch NexgenRX Inc. in the live analysis
One click puts NexgenRX Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
